



Molecular Research on Colorectal Cancer

Guest Editors:

Dr. Teresa Catalano

Department of Clinical and
Experimental Medicine,
University of Messina, via
Consolare Valeria, 98125 Messina,
Italy

Dr. Gitana Maria Aceto

Department of Medical and Oral
Sciences and Biotechnologies,
University G. d'Annunzio of
Chieti-Pescara, 66100 Chieti, Italy

Deadline for manuscript
submissions:

closed (31 December 2023)

Message from the Guest Editors

Colorectal Cancer (CRC) is the third most common malignancy in humans. The incidence of CRC varies widely around the world, as the risk of developing this disease is influenced by environmental, genetic and lifestyle factors. Currently, primary prevention and early detection appear to be necessary weapons to increase survival rates.

Many risk factors can alter the microbiome composition and deregulate immune responses by inducing inflammation. In the colonic epithelium, chronic inflammation and reactive oxygen species (ROS) production impair pathways deputed to tissue turnover and DNA damage repair through metabolic alterations in the intestinal microenvironment.

Adenomas originate from altered functional homeostasis of the intestinal epithelium and are the main precursor of CRC in both high-risk family groups and the general population. Molecular characterization of the interactions between tumor cells and the microenvironment, during tumor progression, could allow the identification of biomarkers, useful for preventive approaches to CRC.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)